American Society of Hematology

SHERPA: Blue

People

  1. O'Reilly
    O'Reilly
  2. Levine
    Levine
  3. Kernan
    Kernan
  4. Scheinberg
    Scheinberg
  5. Papadopoulos
    Papadopoulos
  6. Castro-Malaspina
    Castro-Malaspina
  7. Young
    Young
  8. Papaemmanuil
    Papaemmanuil
  9. Jakubowski
    Jakubowski
  10. Perales
    Perales

Groups

  1. Center for Molecular Imaging and Biotechnology (673)
  2. GSK Faculty (673)
  3. Department of Medicine (572)
  4. Center for Hematologic Malignancies (540)
  5. Tow Center for Developmental Oncology (TCDO) (480)
  6. Hematologic Malignancies, Division of (463)
  7. Sloan Kettering Institute Faculty (425)
  8. Adult Leukemia (307)
  9. Pediatrics, Department of (290)
  10. Executive Committee, Center for Hematologic Malignancies (282)
Search Within
  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Meeting Abstract (510)
  2. Journal Article (155)
  3. Guidelines (3)
  4. Research Letter (2)
  5. Review (2)
  6. Editorial (1)
Groups
  1. Center for Molecular Imaging and Biotechnology (673)
  2. GSK Faculty (673)
  3. Department of Medicine (572)
  4. Center for Hematologic Malignancies (540)
  5. Tow Center for Developmental Oncology (TCDO) (480)
  6. Hematologic Malignancies, Division of (463)

More Groups

People
  1. Richard O'Reilly (257)
  2. Ross Levine (182)
  3. Nancy Kernan (119)
  4. David Scheinberg (110)
  5. Farid Boulad (100)
  6. Trudy Small (97)

More People

Years
  1. 2024 (5)
  2. 2023 (37)
  3. 2022 (28)
  4. 2021 (25)
  5. 2020 (19)
  6. 2019 (27)

More Years

Publications
  1. Blood (643)
  2. Blood Advances (27)
  3. Hematology-American Society of Hematology Education Program (3)

Results (673)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations
    Journal Article

    Döhner, H.; DiNardo, C. D.; Appelbaum, F. R.; Craddock, C.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Godley, L. A.; Hasserjian, R. P.; Larson, R. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
    Journal Article

    Hoff, F. W.; Blum, W. G.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Archer, K. J.; Patel, P. A.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Molecular taxonomy of myelodysplastic syndromes and its clinical implications
    Journal Article

    Bernard, E.; Hasserjian, R. P.; Greenberg, P. L.; Arango Ossa, J. E.; Creignou, M.; Tuechler, H.; Gutierrez-Abril, J.; Domenico, D.; Medina-Martinez, J. S.; Levine, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
    Journal Article

    Sirenko, M.; Bernard, E.; Creignou, M.; Domenico, D.; Farina, A.; Arango Ossa, J. E.; Kosmider, O.; Hasserjian, R.; Jädersten, M.; Germing, U.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
    Journal Article

    Othman, J.; Potter, N.; Ivey, A.; Tazi, Y.; Papaemmanuil, E.; Jovanovic, J.; Freeman, S. D.; Gilkes, A.; Gale, R.; Rapoz-D'Silva, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Influence of pre-treatment features and therapy choice by physicians on overall survival in older adults with acute myeloid leukemia: A report from the beat AML master trial
    Meeting Abstract

    Borate, U. M.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genomic characterization of newly diagnosed acute myeloid leukemia in patients age 60 years and older; A report from the beat AML master trial
    Meeting Abstract

    Hoff, F. W.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Patel, P. A.; Collins, R. H.; Baer, M. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF)
    Meeting Abstract

    Liu, Q.; Welkie, R. L.; Huang, Y.; Swords, R. T.; Lin, T. L.; Koenig, K. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; Blum, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Interaction between presenting features, co-occurring mutations, MRD and induction treatment influences outcome in adults with NPM1 mutated AML - An analysis of 1357 patients in the UK NCRI AML17 and AML19 studies
    Meeting Abstract

    Othman, J.; Potter, N.; Ivey, A.; Tazi, Y.; Papaemmanuil, E.; Jovanovic, J.; Freeman, S. D.; Gilkes, A.; Thomas, I.; Johnson, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent and target specific cytotoxicity of PRAME TCR mimic CAR T cells in KMT2A-rearranged AML patient-derived xenograft model
    Meeting Abstract

    Kirkey, D. C.; Robinson, L.; Hylkema, T.; Loeb, A.; Ries, R. E.; McKay, C.; Root, C.; Pardo, L.; Loeb, K. R.; Le, Q.; more...
    Blood (2023)

    Fulltext@MSK | Save